Rein Therapeutics (RNTX)CEO bought ~$362

~$362

Approx. value · 161 sh @ $2.25

161

Holds after · shares reported

Traded

Dec 5, 2024

Filed

Dec 9, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 5, 2024 · this disclosureInsiderCEO purchased ~$362 of RNTX shares in the open market

What came next

1. Dec 5, 2024InsiderCEO purchased ~$535 of RNTX shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Rein Therapeutics

OQRO holds no insider, Congress, fund or contract record for Rein Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RNTX page.

Other recent filings by James Brian Windsor, President and CEO

• SEC Form 4 at Rein Therapeutics (RNTX)May 13, 2026
• SEC Form 4 at Rein Therapeutics (RNTX)Dec 9, 2024

The full history of James Brian Windsor, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Rein Therapeutics

• SEC Form 4May 29, 2026
• SEC Form 4May 29, 2026
• SEC Form 4May 29, 2026
• SEC Form 4May 29, 2026
• SEC Form 4May 13, 2026
• SEC Form 4Nov 18, 2025

Everything OQRO holds on this company is on its RNTX page.